Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 16/20 | 0.57 |
| ▸ | WNT1 | P04628 | 12/20 | 0.57 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30142335 | 1.00 | DYRK1A (0.57) | DYRK1AWNT1USP30NPC1RAB9A | |
| SCHEMBL30142316 | 0.93 | DYRK1A (0.64) | DYRK1AWNT1NPC1RAB9A | |
| SCHEMBL30142288 | 0.82 | GSK3B (0.57) | DYRK1AWNT1 | |
| SCHEMBL30142387 | 0.82 | DYRK1A (0.62) | DYRK1AWNT1NPC1RAB9A | |
| SCHEMBL30142298 | 0.79 | GSK3B (0.53) | DYRK1AWNT1NPC1RAB9A | |
| SCHEMBL20069732 | 0.77 | L3MBTL1 (0.57) | DYRK1AWNT1USP30 | |
| SCHEMBL20068957 | 0.77 | KDM5A (0.57) | DYRK1AWNT1 | |
| SCHEMBL29732688 | 0.75 | NPC1 (0.74) | DYRK1AWNT1USP30NPC1RAB9A | |
| SCHEMBL6950689 | 0.75 | NPC1 (0.74) | DYRK1AWNT1USP30NPC1RAB9A | |
| SCHEMBL30142314 | 0.74 | GSK3B (0.45) | DYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | EIF2AK4, GCN1, GNAI2 | DYRK1A 3529/4885WNT1 2112/4885USP30 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.